Glutamate (Glu) neurotoxicity is an important element of a number of neurological disorders including central nervous system (CNS) ischemia. We evaluated the effects of the novel AMPA Glu antagonist L Y293558 on functional neurological outcome in two rabbit stroke models. In the reversible spinal cord ischemia model, ischemia of the caudal lumbar spinal cord was produced by temporary occlusion of the abdominal aorta. L Y293558 was administered 5 min after recirculation as a 16 mg/kg i.v. bolus followed by 2.2 mg/kg infused over I h. Control animals received saline. L Y293558 signifi-
The amino acid glutamate (Glu) is the principal excitatory neurotransmitter in the mammalian brain (Fonnum, 1984) . Excessive neuronal release of Glu may be pivotal early on in the sequence of events resulting in ischemic cell death in the central ner vous system (CNS) . Several lines of evidence sup port this "excitotoxic hypothesis." The application of GIu to neurons in culture (Prehn et aI., 1993) or intracerebrally in rats (Beal et aI., 1991) results in neuronal degeneration similar to that in ischemic injury. Excitatory amino acids, including gluta mate, are elevated in ischemic brain (Benveniste et cantly increased the duration of ischemia required to pro duce paraplegia, from 30.5 ± 15.8 min (mean ± SD) con trols to 50.1 ± 11.5 in treated animals (p < 0.01). In an irreversible model of cerebral ischemia, 50 J.1m plastic microspheres were injected into the carotid artery and lodged in the cerebral microvasculature. LY293558 did not significantly reduce neurological damage in this model. These data suggest that L Y293558 may have therapeutic benefit following some types of ischemic injury. Key Words: LY293558-AMPA-Glutamate Ischemia-Rabbits. aI., 1984; Matsumoto et aI., 1993; Zini et aI., 1993; Takagi et aI., 1993) , and brain regions particularly susceptible to ischemia express a high level of Glu receptors (Cotman and Iversen, 1987) . The infarct volume resulting from an ischemic insult is signifi cantly correlated with the magnitude of Glu release in brain (Takagi et aI., 1993) , and a Glu release in hibitor reduced ischemic brain injury (Leach et aI., 1993) . Glu neurotoxicity is thought to be a feature of a number of pathological conditions including epi lepsy (Wuarin et aI., 1992; Dingledine et aI., 1990; Steen et a\., 1983; Martin et aI., 1992) , Alzheimer's disease (Advokat and Pellegrin, 1992) , and Parkin son's disease (Jacewicz et a\., 1990; Smith et aI., 1988; Turski et aI., 1991) .
Glu receptors may be divided pharmacologically into a number of receptor subtypes, including the N-methyl-D-aspartate (NMDA) receptor and the AMPA receptor (McLennan, 1983; Monaghan et a\., 1983; Petralia and Wenthold, 1992) . Competi tive (Sauer et aI., 1993; Madden et aI., 1992b; Gotti et aI., 1990; Nellgard and Wieloch, 1992a) and non competitive (Kochhar et al., 1988; Ozyurt et aI., 1988; Gotti et aI., 1990; Nellgard and Wieloch, 1992a ) NMDA antagonists reduce ischemic injury, although this neuroprotectant effect has been attrib uted to drug-induced hypothermia by some authors (Buchan, 1992; Hayward et aI. , 1993) . Although NMDA antagonists consistently reduce neural in jury following irreversible focal ischemia, these compounds have a variety of undesirable side ef fects, including sedation (Kochhar et aI. , 1991) , psychotomimetic properties (Koek et aI. , 1988) , cardiac (Soltis and DiMicco, 1992) and respiratory dysfunction (Foutz et aI. , 1988) , and potential inter ference with learning and memory (Advokat and Pellegrin, 1992 ). These side effects may limit the potential therapeutic usefulness of MK-801 and similar compounds in CNS ischemia.
Compounds that block the AMPA Glu receptor also appear to possess neuroprotectant properties (Nellgard and Wieloch, 1992b; Sheardown et aI. , 1990; Gill et aI. , 1992; Bullock et aI. , 1994a) , and it has been reported that simultaneous blockade of both NMDA and AMPA receptors decreases dam age in retina (Mosinger et aI. , 1991) and brain (N ell gard and Wieloch, 1992a) . Although numerous re ports have described the reduction of CNS injury by AMPA antagonists using histological measures, there were few data relating these findings to neu rological outcome. In the present experiments, we have examined the ability of the novel AMPA antagonist L Y293558 to improve functional out come following CNS ischemia. Unlike most previ ously examined AMPA antagonists (e.g., CNQX, NBQX), L Y293558 is highly water-soluble and is systemically active (Ornstein et aI. , 1993) . Two ischemia models were used, a rabbit spinal cord ischemia model (RSCIM), (Zivin and DeGirolami, 1980) in which the abdominal aorta is reversibly oc cluded with a snare ligature, and the microsphere cerebral embolization model (MCEM) (Zivin et aI. , 1987) , in which cerebral ischemia is induced by em bolization with numerous small plastic micro spheres injected into the carotid circulation.
In addition to the effects of L Y293558 on neuro logical function, we also measured the time course of plasma concentrations of the compound in isch emic and nonischemic animals, and the effects of LY293558 on blood pressure (BP).
MATERIALS AND METHODS

AMP A antagonist
LY293558 [( -)-3S.4aR,6S,8aR-6-(2( 1(2)H-tetrazol-5yl)eth-l ,2,3,4,4a, 5 ,6, 7 ,8,8a-decahydroisoquinoline-3carboxylic acid] is a selective antagonist for the excitato ry amino acid AMPA receptor. LY293558 is a highly wa ter-soluble drug suitable for i. v. administration, and its properties have recently been described in detail (Orn stein et aI., 1993) . Vol. 16. No.5, 1996 Animals Male New Zealand white rabbits (2-3 kg) were individ ually housed and provided food and water ad libitum be fore surgery.
RSCIM
Animals were anesthetized with halothane. Using a paramedial incision, the abdominal aorta was exposed at the level of the renal arteries. Small-diameter plastic tub ing was placed around the aorta just distal to the left (more caudal) renal artery. The ends of the tubing were threaded through a small plastic button and then through a larger-diameter plastic tube, forming a snare ligature. The incision was closed around the tube so that the free ends of the tubing were accessible externally. Animals were allowed to recover for at least 3 h and appeared to behave normally prior to the initiation of ischemia. Aortic occlusion was performed by pulling and clamping the small tube around the aorta. Complete paraplegia was observed in all animals within 2 min of occlusion. Occlu sion durations encompassing all grades of neurological function, from complete recovery to permanent hindlimb paralysis, were selected. At the end of the ischemic pe riod, the tubing was released to restore blood flow through the aorta. The tubing was removed and the ab dominal wall closed with wound clips without further an esthesia. Animals were returned to their home cages and maintained for 4 days. Animals dying within this period were excluded from the study to ensure that no animals with aortic thrombosis were included in the data analysis. Neurological function was evaluated 18 h and 4 d after ischemia/reperfusion by two observers blind to animal treatment and duration of ischemia. Animals were classi fied by the presence or absence of paraplegia. Paraplegic animals showed no motor response to noxious stimuli in the hind limbs and were totally incontinent. Rabbits that were not paraplegic were either normal or had some mo tor function of the hind limbs, even if voluntary move ment was only barely detectable. Bowel and bladder function were variable. If it was difficult to ascertain whether an animal was totally paraplegic, the animal was classified as paraplegic.
At 5 min after the onset of reperfusion, animals re ceived saline (n = 11) or LY293558 (n = 14) as a 16 mg/kg initial bolus followed by 2.2 mg/kg infused at a constant rate for 1 h.
MCEM
An incision was made lateral to the trachea to expose the right common carotid artery. The external carotid was ligated just rostral to the carotid bifurcation. A catheter, filled with heparinized saline and sealed with an injection cap, was inserted anterograde into the common carotid artery and secured with ligatures. The incision was closed with the distal end of the catheter accessible externally. Animals were allowed to recover from anesthesia for at least 2 h and appeared to behave normally prior to em bolization. Plastic microspheres, 50 J..l m, (New England Nuclear, Boston, MA, U.S.A.) were carefully weighed for each animal and mixed with a tracer quantity of 15 J..l m micro spheres labelled with 5 1Cr. Microspheres were sus pended in a solution of 0.05% polysorbate-80 in normal saline and sonicated at high power for 10 min. The amount of radioactivity present in each microsphere dose was measured using a gamma counter, and microspheres were transferred to individual 0.5-ml gas-tight syringes (Hamilton Co., Reno, NV, U.S.A.) and sonicated at low power until embolization. The quantity of microspheres injected was varied from animal to animal to provide a range of microsphere doses encompassing all grades of neurological function. Animals were restrained briefly during embolization. The heparinized saline was with drawn from the carotid artery catheter and the micro sphere suspension was rapidly injected. The injection system was flushed with 3 ml normal saline, avoiding the formation of air bubbles within the catheter or injection cap. Animals were returned to their home cages for sub sequent neurological evaluation.
Neurological function was evaluated 18 h after embo lization by two observers blind to animal treatment and microsphere dose. Each animal was evaluated as either functional (alert and able to right itself) or abnormal (dead or having unequivocal neurological deficit such as greatly reduced level of spontaneous activity, inability to stand, or markedly uncoordinated movements). Following eval uation, animals were killed using Beuthanasia-D (Scher ing-Plough, Kenilworth, NJ, U.S.A.) and their brains re moved. Radioactivity trapped in the brain was measured using a gamma counter. The total radioactivity recovered in the brain was compared to the specific activity of the injected microsphere dose to determine the weight of mi crospheres trapped in the brain.
Three groups of animals received i. v. infusions of L Y293558. In the first group (n = 23), animals received a 16 mg/kg dose followed by 2.2 mg/kg infused at a constant rate over 1 h, initiated 5 min after embolization. In the second group (n = 10), animals received 8 mg/kg fol lowed by 1.1 mg/kg infused over 1 h. In the third group (n = 8), animals received 16 mg/kg, followed by bolus ad ministration of an additional 2.2 mg/kg once an hour for 18 hours. Each treatment group was compared with a group (of similar n) of saline-treated control animals.
Data analysis
Neurological damage as a function of ischemic insult was analyzed using quantal dose-response analysis tech niques described previously (Waud, 1972; Zivin and Waud, 1992) . A computer was used to fit logistic (S shaped) curves to the fraction of abnormal animals as a function of ischemia duration (RSCIM) or weight of mi crospheres trapped in the brain (MCEM). Using this tech nique, the ischemic duration or microsphere weight nec essary to produce clinically apparent neurologic deficit in 50% of a group of subjects may be computed for each experimental condition (ET 5 0 in the RSCIM, for effective time; ES 5 0 in the MCEM, for effective stroke). Pharma cological manipulations that improve neurological out come will increase the ET 5 0 or ES 5 0, implying a shift of the dose-response curve to the right. Control and treat ment animals were compared using {-tests, with p < 0.05 considered significant for all comparisons. This quantal bioassay technique allows high efficiency determination of dose-response curves using a relatively small number of subjects.
Concentration of LY293558 in plasma
Blood plasma levels of L Y293558 were evaluated using a separate group of 10 animals. Three animals received abdominal aorta occluders as previously described, and each animal was subjected to 25 min occlusion of the abdominal aorta. Four animals received carotid artery catheters and were embolized with radiolabelled micro-spheres as described previously. Nonischemic animals underwent abdominal surgery, and snare ligatures were placed but not occluded. At 5 min after reperfusion (spi nal cord ischemia) or microsphere injection (cerebral em bolization animals), animals received L Y293558, 16 mg/ kg i.v., followed by 2.2 mg/kg infused over 1 h. Blood samples were collected at 15, 30, 60, and 90 min after embolization or reperfusion, and plasma was analyzed for L Y293558 concentration by capillary gas chromatogra phy (GC)/mass spectrometry (MS). Briefly, the method involved extraction of L Y293558 from plasma samples with anion exchange cartridges, followed by derivatiza tion of the carboxylic acid in L Y293558 to its methyl es ter, and acylation of the secondary amines with tri fluroacetic anhydride. Derivatized products were then quantified using capillary GC/MS, with positive electron impact detection. The limit of detection for the assay was 0.05 f1g/ml. The plasma concentrations were evaluated using a mixed-factorial design analysis of variance (ANOVA).
Effects of L Y293558 on blood pressure
The effects of L Y293558 on BP were evaluated in three animals. BP was monitored using a carotid artery catheter oriented retrograde and connected to a physiograph. BP was monitored for 20 min prior to drug treatment. L Y293558 (16 mg/kg initial bolus followed by 2.2 mg/kg infused over I h) was administered i. v. The effects of L Y293558 on BP were evaluated using repeated-mea sures ANOV A.
RESULTS
L Y293558 substantially improved neurological outcome following reversible ischemialreperfusion of the rabbit spinal cord. The duration of ischemia and neurological outcome at 18 h for the two groups are presented in Table 1 . In the control animals, the duration of ischemia associated with a 50% proba bility of paraplegia was 30. 5 ± 15.8 min (ETs o ± SD). In treated animals, this increased significantly to 50.1 ± 11.5 min (p < 0.01). These data are illus trated in Fig. 1 . This significant increase in ET 50 was maintained 4 days following ischemialreper fusion.
In the cerebral embolization model, no significant neuroprotectant effect was observed. In the first experiment, the quantity of microspheres associ ated with a 50% likelihood of permanent neurolog ical injury in the control group was 0. 50 ± .40 mg (ESs o ± SD). In animals receiving a L Y293558 16 mg/kg bolus followed by a 2.2 mg/kg infusion for 1 h, the ES50 was 0. 64 ± .30, not significantly differ ent from control. In the second experiment, when the dose was halved, the ESs o for the control and treated groups were, respectively, 0.49 ± .21 and 0.34 ± .30 mg. Repeated administration for 18 h also failed to significantly improve neurological out come in this model. L Y293558 significantly increased both systolic 0.04]. Diastolic BP also increased significantly from 78.33 ± 2. 9 to 98.33 ± 7. 6 [F(l,2) = 48, p = 0.02]. Plasma L Y293558 declined significantly (p < 0.000 1) over 90 min, despite the 16.0 mg/kg bolus followed by 2.2 mg/kg infusion for 1 h. Clearance of L Y293558 was not significantly different in micro sphere embolization, spinal cord occlusion, and nonischemic control animals (see Fig. 1 ).
Animals treated with L Y293558 displayed mild sedation and ataxia for several hours after drug ad ministration, although the sedative effect of this compound appeared less severe than we have ob served with NMDA antagonists (e. g. , MK-80l) (Kochhar et aI. , 1988; Madden et aI. , 1992a) . All animals had fully recovered by the 18-h evaluation.
DISCUSSION
AMP A antagonists have reduced infarct volume (Smith and Meldrum, 1992; Gill et aI. , 1992; Buchan et aI. , 1991; Bullock et aI. , 1994b) and neuronal de generation in hippocampus, striatum, cortex, and cerebellum (Sheardown et aI. , 1990; Diemer et aI. , 1992; Nellgard and Wieloch, 1992b; Buchan et aI. , 199 1; Balchen and Diemer, 1992; Nellgard and Wie loch, 1992a) in several animal models. De Graba and coworkers (1994) recently demonstrated im proved functional outcome following administration of 2,3-dihydroxy-6-nitro-7 -sulfamoyl-benzo(F) quinoxaline (NBQX). Here, we show that adminis tration of the AMPA antagonist L Y293558 signifi cantly improved neurological function following reversible spinal cord ischemia but not irreversible cerebral ischemia. Neuroprotection was observed at both 18-h and 4-day evaluations, indicating that the neuroprotective effects of L Y293558 persist af ter the compound has been cleared from circulation after transient ischemia. L Y293558 improved neu rological outcome in the reversible spinal cord isch emia model but not in the irreversible cerebral em bolization model. This may be attributable to differ ing sensitivities of the two models. In this RSCIM, a difference in the survival of a relatively small number of motor neurons may produce a detectable improvement in hindlimb function, whereas in the MCEM, survival of a large number of neurons is probably necessary to detect neuroprotection. It is also possible that the short half-life of the com pound and the failure to reach a steady-state drug concentration, despite the continuous infusion pro cedure, merely delayed the development of neural injury in the irreversible ischemia model. The de cline in circulating L Y293558 may not have been important in the spinal cord model, in which isch emia is followed by reperfusion, but may have been critical in the microsphere model. Bullock et al. (l994b) recently reported that this compound re duced the volume of ischemic injury following irre versible cerebral ischemia in cats, when the animals were killed after 6 h of ischemia. Comparison of these two studies must be made with caution, how ever, because there were a number of methodolog ical differences. In that study, animals were anes thetized and their BPs and pHs manipulated, and a constant drug level was maintained, throughout the 6-h period until killing. It should also be noted that we have previously demonstrated significant neuro protection following administration of NMDA re ceptor antagonists in this model (Kochhar et aI. , 1988; Madden et aI., 1992b) , and it is unclear whether the present results indicate that AMPA antagonists are not effective in this type of embolic ischemia or whether the dose was insufficient.
Administration of 16 mg/kg L Y293558 rapidly in creased BP by an average of 15 mm Hg (systolic) and 20 mm Hg (diastolic). The effectiveness of this compound in the reversible spinal cord ischemia model, but not in the irreversible cerebral emboliza tion model, may reflect enhanced reperfusion of the spinal cord resulting from elevated BP. The effects of hypertension in irreversible cerebral ischemia are controversial. A large body of evidence from the spontaneously hypertensive rat indicates that hy pertension at embolization may exacerbate isch emic injury. Induced hypertension, however, has reduced neurological injury in some CNS ischemia preparations (Sterz et aI., 1990; Cole, Drummond et aI. , 1990; Patel et aI. , 199 1) . We have recently ob served a similar pattern of results with a hemoglo bin solution that elevates BP (Bowes et aI. , 1994) . At the moment, the precise relationship between BP and neurological injury is unclear. Other phys iological variables, e. g. , cerebral blood flow, should also be examined.
AMPA antagonists as a treatment for CNS isch emia are attractive because they do not have the potential for psychiatric side effects, as do NMDA antagonists. Because AMPA antagonists do not bind to the phencyclidine receptor, they may pre vent excitotoxic injury with fewer psychiatric side effects, and, in animals, drugs that block the AMP A receptor appear less sedating than NMDA antago nists (Nellgard and Wieloch, 19920) . It is also pos sible that combined NMDA and AMPA therapy may improve neurological function to a greater ex tent than either substance alone. This has been ob served histologically in neurodegeneration of retina and brain (Mosinger et aI. , 1991; Nellgard and Wie loch, 19920) , but not, to our knowledge, in a func tional neurological assay. The present experiments suggest that AMPA antagonists may improve neu rological function following some types of CNS ischemia. In contrast to most other CNS ischemia models, these studies have assessed neural injury in awake and unanesthetized animals, limiting the ef fects of confounding variables such as temperature or anesthesia. These results suggest a potentially beneficial role of AMP A antagonists in the pharma cological treatment of CNS ischemia, although car diovascular, blood flow, and potential side effects require further study.
